At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
Pembrolizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Pembrolizumab for Recurrent Merkel Cell Carcinoma and 4 related conditions. Completed, enrolled 50 participants across 13 sites.
Detailed Summary
This phase II trial studies how well pembrolizumab works in treating patients with Merkel cell cancer that cannot be removed by surgery or controlled with treatment, or has spread to other parts of the body. Pembrolizumab may stimulate the immune system to identify and destroy cancer cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Merkel Cell Carcinoma, Stage III Merkel Cell Carcinoma AJCC v7, Stage IIIA Merkel Cell Carcinoma AJCC v7, Stage IIIB Merkel Cell Carcinoma AJCC v7, Stage IV Merkel Cell Carcinoma AJCC v7
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartNov 2014
Primary CompletionFeb 2018
Study CompletionDec 2021
TodayJul 2026
First PostedOct 17, 2014
Enrollment StartNov 25, 2014
Primary CompletionFeb 6, 2018
Study CompletionDec 15, 2021
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 11.7 years ago
Interventions
Laboratory Biomarker Analysisother
Ancillary studies
Pembrolizumabbiological
Given IV